Similar Items: Fractionation gives therapeutic benefit in animal model of [Lu]Lu-PSMA-617 therapy of prostate cancer
- Dosimetry of [Lu]Lu-PSMA therapy in a hemodialysis patient: a case study
- Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
- PSMA‐Targeting Macrophage Membrane‐Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer
- Correction: Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein
- Comparative evaluation of [¹⁸F]FAPI-42 and [¹⁸F]PSMA-1007 PET/CT for lesion detection and uptake in prostate cancer across disease stages
- Most ReLU Networks Admit Identifiable Parameters